The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.
Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular disease retrieved 25 May 2024 from https://medicalxpress.com/news/2024-05-semaglutide-kidney-function-individuals-overweight.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Nov 13, 2023Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide alleviates metabolic-linked liver disease in people with HIVFor people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online April 30 in the Annals of Internal Medicine.
Read more »
Semaglutide improves heart failure symptoms and reduces loop diuretic doseSemaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF) regardless of diuretic use, according to late breaking research presented today at Heart Failure 2024, a scientific congress of the European...
Read more »
Sustainable weight loss with personalized semaglutide dosingNew research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits of giving personalised doses of semaglutide to patients taking part in a weight loss programme and tapering them off the medication when they reach their target weight.
Read more »
Semaglutide shows significant weight loss and health benefits in four-year obesity studyA study in Nature Medicine evaluated the effects of semaglutide on weight and anthropometric outcomes in adults with obesity but without diabetes, finding significant weight loss and improved health metrics over four years. The study also highlighted the safety and tolerability of semaglutide across different BMI categories.
Read more »
‘If NHS can afford it, people with obesity should have Semaglutide,’ says weight loss expertWe were joined by Professor Frank Joseph, a weight loss expert who was one of the investigators in the study.
Read more »
Semaglutide significantly reduces risk of complications in patients with type 2 diabetes, study revealsA pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease.
Read more »